Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.52 EUR | +0.80% | +0.80% | +4.56% |
Apr. 22 | BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment | MT |
Apr. 11 | Gerresheimer shares down on outlook, but key contracts confirmed | RE |
Sales 2024 * | 78.6M 84.48M | Sales 2025 * | 82.25M 88.4M | Capitalization | 35.88M 38.56M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.07M | Net income 2025 * | - 0 | EV / Sales 2024 * | 0.59 x |
Net Debt 2024 * | 10.6M 11.39M | Net Debt 2025 * | 6.9M 7.42M | EV / Sales 2025 * | 0.52 x |
P/E ratio 2024 * |
-25
x | P/E ratio 2025 * |
100
x | Employees | 1,071 |
Yield 2024 * |
2.2% | Yield 2025 * |
3.8% | Free-Float | 100% |
1 day | +0.80% | ||
1 week | +0.80% | ||
Current month | +0.80% | ||
3 months | +1.20% | ||
6 months | -8.03% | ||
Current year | +4.56% |
Managers | Title | Age | Since |
---|---|---|---|
Kimmo Herranen
CEO | Chief Executive Officer | 51 | 04-12-31 |
Kalle Lehtonen
DFI | Director of Finance/CFO | 50 | 23-07-31 |
Director/Board Member | 54 | 93-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Risto Koivula
BRD | Director/Board Member | 56 | 21-08-15 |
Chairman | 58 | 18-06-30 | |
Director/Board Member | 56 | 22-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 2.52 | +0.80% | 4 549 |
24-05-07 | 2.5 | 0.00% | 3,970 |
24-05-06 | 2.5 | 0.00% | 3,697 |
24-05-03 | 2.5 | 0.00% | 184 |
24-05-02 | 2.5 | 0.00% | 2,513 |
Delayed Quote Nasdaq Helsinki, May 08, 2024 at 05:11 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.56% | 38.67M | |
-10.51% | 292M | |
-.--% | 62.2M | |
-20.59% | 60.47M |
- Stock Market
- Equities
- ADMIN Stock